Vontobel Holding Ltd. Sells 1,185 Shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH)

Vontobel Holding Ltd. cut its stake in Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 14.9% in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 6,754 shares of the medical equipment provider’s stock after selling 1,185 shares during the period. Vontobel Holding Ltd.’s holdings in Zimmer Biomet were worth $729,000 as of its most recent SEC filing.

A number of other hedge funds have also recently bought and sold shares of the stock. Crewe Advisors LLC bought a new position in shares of Zimmer Biomet during the 1st quarter worth about $31,000. Bangor Savings Bank bought a new position in shares of Zimmer Biomet during the 3rd quarter worth about $31,000. Family Firm Inc. bought a new position in shares of Zimmer Biomet during the 2nd quarter worth about $33,000. J.Safra Asset Management Corp lifted its holdings in shares of Zimmer Biomet by 712.1% during the 1st quarter. J.Safra Asset Management Corp now owns 268 shares of the medical equipment provider’s stock worth $35,000 after acquiring an additional 235 shares during the period. Finally, Loring Wolcott & Coolidge Fiduciary Advisors LLP MA bought a new position in shares of Zimmer Biomet during the 2nd quarter worth about $43,000. 88.89% of the stock is owned by institutional investors.

Analysts Set New Price Targets

A number of equities analysts have recently commented on ZBH shares. Robert W. Baird reduced their price objective on shares of Zimmer Biomet from $155.00 to $145.00 and set an “outperform” rating for the company in a report on Thursday, August 8th. Piper Sandler downgraded shares of Zimmer Biomet from an “overweight” rating to a “neutral” rating and cut their price target for the company from $140.00 to $115.00 in a report on Monday, July 1st. TD Cowen cut their price target on shares of Zimmer Biomet from $143.00 to $119.00 and set a “hold” rating for the company in a report on Friday, September 6th. BTIG Research lowered their price objective on shares of Zimmer Biomet from $134.00 to $126.00 and set a “buy” rating for the company in a research report on Thursday, October 3rd. Finally, Wolfe Research began coverage on shares of Zimmer Biomet in a research report on Tuesday, September 10th. They set a “peer perform” rating for the company. Two analysts have rated the stock with a sell rating, eleven have issued a hold rating and eight have given a buy rating to the company. Based on data from MarketBeat, Zimmer Biomet has a consensus rating of “Hold” and an average price target of $123.94.

Zimmer Biomet Price Performance

Shares of ZBH opened at $106.31 on Monday. Zimmer Biomet Holdings, Inc. has a 12-month low of $101.47 and a 12-month high of $133.90. The business’s fifty day moving average is $108.11 and its 200 day moving average is $112.19. The company has a quick ratio of 0.63, a current ratio of 1.29 and a debt-to-equity ratio of 0.31. The stock has a market cap of $21.87 billion, a P/E ratio of 23.01, a P/E/G ratio of 1.95 and a beta of 1.02.

Zimmer Biomet (NYSE:ZBH) last issued its quarterly earnings data on Wednesday, August 7th. The medical equipment provider reported $2.01 earnings per share for the quarter, beating the consensus estimate of $1.99 by $0.02. Zimmer Biomet had a return on equity of 12.86% and a net margin of 13.25%. The business had revenue of $1.94 billion for the quarter, compared to analysts’ expectations of $1.94 billion. During the same period last year, the business earned $1.82 EPS. The business’s revenue was up 3.9% on a year-over-year basis. Sell-side analysts anticipate that Zimmer Biomet Holdings, Inc. will post 7.97 earnings per share for the current fiscal year.

Zimmer Biomet Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, October 31st. Shareholders of record on Monday, September 30th will be paid a dividend of $0.24 per share. This represents a $0.96 annualized dividend and a yield of 0.90%. The ex-dividend date is Monday, September 30th. Zimmer Biomet’s dividend payout ratio (DPR) is presently 20.78%.

Zimmer Biomet Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.